Efficacy and safety of humanized interleukin-6 receptor antibody in treatment of systemic juvenile idiopathic arthritis

Lixia ZOU,Meiping LU,Li GUO,Liping TENG,Yiping XU,Qi ZHENG

DOI: https://doi.org/10.3785/j.issn.1008-9292.2017.08.12

2017-01-01

Abstract:Objective: To evaluate the efficacy and safety of humanized anti-IL-6 receptor monoclonal antibody(tocilizumab)in treatment of systemic juvenile idiopathic arthritis(sJIA).Methods: Thirteen sJIA patients admitted between December 2015 and November 2016 and received tocilizumab treatment were enrolled in the study.The complete blood count(CBC), C-reactive protein(CRP), erythrocyte sedimentation rate(ESR),interleukin-6(IL-6)and ferritin levels were measured;American College of Rheumatology Pediatric(ACR Pedi)30/50/70/90 scores were assessed;and the use of glucocorticosteroid and adverse events were documented.Results: Compared with the baseline levels, the CRP and ESR at d3 were decreased(all P <0.05);hemoglobin was increased and platelet was decreased at week 2(all P<0.05),ferritin decreased at week 4,white blood cell(WBC)decreased at week 8 after treatment with tocilizumab(all P <0.05).The level of IL-6 was rising at d3 and week 2 and descending at week 4, but no significant difference was observed compared with the baseline level(all P>0.05).All 13 patients achieved ACR Pedi 30 remission at week 4,61.5%achieved ACR Pedi 90 remission and glucocorticosteroids were withdrawn at week 20.Twenty two adverse events occurred, and infection accounted for 54.5%(12/22); no severe adverse reactions were observed during 20-week follow-up. Conclusion: Tocilizumab is safe and effective in treatment of sJIA, with decreasing inflammation,improving disease activity and reducing glucocorticosteroid use.